10940
532488
DIVISLAB
As of the latest trading session, DIVI S LABORATORIES LTD share price is currently at ₹ 6498, which is down by ₹ -12.00 from its previous closing. Today, the stock has fluctuated between ₹ 6451.00 and ₹ 6542.00. Over the past year, DIVI S LABORATORIES LTD has achieved a return of 7.20 %. In the last month alone, the return has been 0.30 %. Read More...
Smart Investing Starts here !
Trade Smart with Fast Execution & Zero Account Opening Fees
Invest Now
| Particulars | SEP 2025 (Values in Cr) |
|---|---|
| Revenue | 2660.00 |
| Operating Expense | 1886.00 |
| Net Profit | 696.00 |
| Net Profit Margin (%) | 26.16 |
| Earnings Per Share (EPS) | 26.24 |
| EBITDA | 1041.00 |
| Effective Tax Rate (%) | 24.34 |
| Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
|---|---|---|---|---|---|
| AMBALAL SARABHAI ENTERPRISES L | 29.00 | 14.22 | 1.50 | 222.24 | 28.35 / 68.00 |
| BLISS GVS PHARMA LTD | 166.85 | 16.09 | 1.55 | 1763.98 | 105.05 / 190.65 |
| CIPLA LTD | 1523.45 | 22.62 | 3.73 | 123059.91 | 1310.05 / 1672.20 |
| FERMENTA BIOTECH LIMITED | 284.80 | 7.48 | 2.14 | 838.19 | 219.00 / 449.00 |
| Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
|---|---|---|---|---|---|
| AMBALAL SARABHAI ENTERPRISES L | 29.00 | 23.58 | 4.04 | 222.24 | 28.35 / 68.00 |
| AMRUTAJAN HEALTH LTD | 684.65 | 34.91 | 5.78 | 1979.37 | 548.05 / 829.00 |
| ASTRAZENECA PHARMA IND LT | 9049.60 | 97.87 | 28.31 | 22624.00 | 6301.00 / 10653.05 |
| BLISS GVS PHARMA LTD | 166.85 | 22.52 | 1.59 | 1763.98 | 105.05 / 190.65 |
Choose a Plan That Suits Your Goals and Needs
Divis Laboratories reported consolidated sales of ₹2,410 crore in Q1 FY26, compared with ₹2,118 crore in Q1 FY25. Operating profit stood at ₹729 crore in Q1 FY25-26 versus ₹622 crore in Q1 FY24-25, with an operating margin at 30% in FY25-26 against 29% in FY24-25. Net profit came in at ₹545 crore in Q1 FY25-26, down from ₹430 crore in Q1 FY24-25. These results reflect the company’s operating performance and financial outcome for the quarter.
Date Source: screener.in, and corporate filings on NSE/BSE
Divis Laboratories reported consolidated sales of ₹9,360 crore in FY24-25, compared with ₹7,845 crore in FY23-24. Operating profit stood at ₹2,973 crore in FY24-25 versus ₹2,210 crore in FY23-24, with margins at 32% in FY24-25 against 28% in FY23-24. Net profit came in at ₹2,191 crore in FY24-25, up from ₹1,600 crore in FY23-24. These consolidated results reflect the company’s annual operating performance and financial outcome for the year.
Date Source: screener.in, and corporate filings on NSE/BSE
Divis Laboratories declared a dividend of ₹30 per share with an ex-date of 25 July 2025. In the previous year, the company announced ₹30 per share on 2 August 2024, while in FY23 the payout was ₹30 per share on 11 August 2023. In FY22, it was ₹30 per share. These dividend announcements reflect the company’s policy of consistent shareholder payouts.
Date Source: screener.in, and corporate filings on NSE/BSE
Divi’s Laboratories is today recognised as one of India’s leading pharmaceutical exporters and among the largest Active Pharmaceutical Ingredient (API) makers globally. Its footprint extends across more than 100 countries, and operations cover APIs, intermediates, and nutraceuticals. While much of its revenue comes from generics, Divi’s also plays a quieter but crucial role through custom synthesis — supporting multinational innovators across the entire drug lifecycle, from early clinical requirements to late-stage scale-ups.
The company’s origins lie in research. Established in 1990 as Divi’s Research Centre, the initial focus was clear: building process capabilities in intermediates and bulk actives for other manufacturers. By 1994, the entity had evolved into Divi’s Laboratories Limited, signalling ambitions that stretched beyond contract research. In practice, the next few years were about building credibility. Between 1991 and 1993, several commercial processes were developed, laying the foundation for scale.
Manufacturing followed swiftly. Unit I at Choutuppal, near Hyderabad, was commissioned in 1995. Global recognition arrived soon after — ISO-9002 certification in 1997, followed by a European certificate of suitability for Naproxen in 1999. Occupational safety standards were acknowledged too, with OHSAS-18001 in 2001. This regulatory grounding was not incidental; for a company looking to service regulated markets, compliance was an asset as much as chemistry.
By 2002, expansion was unavoidable. Unit II at Chippada, near Visakhapatnam, came up, and a year later the firm also set up a research hub at Vizag. That same year, Divi’s tapped the public markets through an IPO, listing on both the BSE and NSE. Funds were channelled into capacity additions, machinery upgrades, and scaling research infrastructure. It was a period of calculated risk-taking — investments in facilities often ran into hundreds of crores, but the demand outlook from global pharma supported the bet.
The mid-2000s marked the SEZ push. In 2006, Divi’s secured government approval for a sector-specific SEZ for pharmaceutical ingredients, converting Unit II into an Export Oriented Unit. By 2007–08, a 250-acre Pharma SEZ was in place at Chippada, with nutraceutical manufacturing commencing commercial production in mid-2008. At this stage, the portfolio was already expanding: nine new products in 2008–09, another seven in 2009–10, and as many as 21 in 2010–11, spread across generic APIs and custom synthesis.
By 2011, the DSN SEZ Unit was operational, adding further capacity to capture new opportunities in generics and synthesis. Routine inspections by the US FDA, KFDA, COFEPRIS and European regulators became part of our normal course of business.
The reinvestment theme continued in the form of brownfield investments announced in FY2019 that amounted to almost ₹1,200 crore, across Visakhapatnam and Telangana. These brownfield investments are fundamentally a combination of debottlenecking and backwards integration investments that extend to 2020-21 and onward, even in a pandemic environment. It is worth noting that operations were deemed essential, which allowed Divi's to continue production through lockdowns; they rarely stopped running. e.Wastewater treatment modernisation, upgrades to utilities and capital redeployments for the purposes of custom synthesis all reinforced a broader strategy — investing to not only grow organic capacity but also to instil compliance and sustainability as part of the manufacturing backbone.
By FY2021, both the DC and DCV SEZ units were fully operational, and ₹400 crore of capex was invested to support the acceleration of new synthesis projects. The expansion train did not stop in 2021. In April 2023, Divi commissioned Unit III at Kakinada, Andhra Pradesh to further broaden its manufacturing capabilities.
At present, Divi's is operating six large facilities, which are also supported by research centres in Hyderabad and its production locations. The subsidiaries in the US and Europe support access to nutraceutical products aligned with proximity to customers. The products produced vary across therapeutic areas, with experience supporting scale and compliance.
30 years post inception, the company's growth represents more than just size. It is an example of how a research-based origin can grow into a global manufacturing destination. The company has achieved this position by consistently investing in compliance with regulations as well as a mix of generics and custom synthesis. The way forward is about sustainability with compliance, leveraging economies of scale, and maintaining a balance between investment and return, the same perspectives that have built the company to date.
Who is the CEO of Divi’s Lab?
The CEO of Divi’s Lab oversees the company’s strategic operations and long-term vision. Under their leadership, Divi’s Lab has maintained its strong market position, and their decisions play a crucial role in shaping the company’s performance. The CEO’s leadership directly influences the Divi’s Lab share price as they focus on sustaining growth and expanding the company’s global footprint. Investors closely watch the CEO’s direction as it impacts both the company’s performance and its market valuation.
When was Divi’s Lab established?
Divi’s Lab was established several decades ago, marking its entry into the pharmaceutical sector with a focus on innovation and research. Since its inception, the company has seen steady growth in both its operations and market value. The establishment of Divi’s Lab set the foundation for its current market success, with the Divi’s Lab share price reflecting its long-standing reputation in the industry. Over the years, the company has consistently expanded, becoming a key player in the pharmaceutical market.
What factors influence the Divi’s Lab share price?
Several factors influence the Divi’s Lab share price, including the company’s financial performance, product pipeline, and broader industry trends. Key internal factors such as revenue growth, profitability, and operational efficiency are critical in shaping investor sentiment. External influences like regulatory changes, market conditions, and competitive pressures also play a role. Investors and stakeholders closely monitor these variables to gauge the potential movement of the Divi’s Lab share price, especially in light of evolving market dynamics.
Is Divi’s Lab debt free?
Divi’s Lab maintains a relatively low debt level, positioning itself as a financially stable company. While it may have some debt, it is well-managed and does not pose significant risks to the company’s overall performance. This debt strategy helps maintain investor confidence in the company’s future, positively influencing the Divi’s Lab share price. The company’s balance sheet reflects its prudent financial management, allowing it to focus on growth while maintaining a healthy capital structure.
How has the Divi’s Lab share price performed over the past year?
The Divi’s Lab share price has experienced moderate fluctuations over the past year, largely influenced by the company’s quarterly results and external market conditions. While the price has seen some downturns, it has also shown resilience, particularly during periods of positive financial performance. Overall, the Divi’s Lab share price has remained stable, reflecting the company’s solid position in the pharmaceutical sector. Investors continue to monitor future performance closely to anticipate potential shifts in the share price.
Divi's Laboratories Limited is one of the leading pharmaceutical companies in the world, manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceuticals. The Company is one of the world's largest API companies, with two manufacturing units and a market presence across 100 countries. It is engaged in the manufacture of Active Pharmaceutical ingredients (API's), Intermediates and Nutraceutical ingredients with predominance in exports. In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management. It is among the largest pharmaceutical companies in India with a portfolio of approx. 160 products across diverse therapeutic areas. Presently, it has 6 manufacturing facilities and market presence across several countries.
The company has two subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products and to provide a greater reach to customers within these regions. The company has Research Centers at Sanathnagar, Hyderabad and at the manufacturing sites. Research Centre at Sanathnagar primarily focuses on custom synthesis, contract research for MNC companies as also future generics involving processes like route design, route selection, establishing gram scale process and structural confirmation.
Divi's Laboratories Limited was established in year 1990 as Divis Research Center Limited (DRC) with Research & Development as their prime fundamental. In 1994, they changed their name to Divis Laboratories Limited to reflect their growing area of operations.
During the year 1991-93, the company developed several commercial processes for intermediates and bulk actives and supplies to manufacturing majors.
In the year 1995, the company started operations in their manufacturing facility (Unit I) at Choutuppal near Hyderabad. In the year 1997, the company was certified as ISO-9002 compliant by SGS-Yarsley of U.K. In the year 1999, European Directorate gave a 'Certificate of Suitability' (CoS) for Naproxen produced by the company. In the year 2001, the company received OHSAS-18001 Certification from BVQI of London for their Occupational Health and Safety Management Systems.
In the year 2002, the company commenced setting up of their second manufacturing facility (Unit II) at Chippada near Visakhapatnam. In the year 2003, they opened a new research center christened 'DRC-Vizag' for fundamental research in selected niche business core segments. The company went for initial public offering (IPO) and their shares were listed on Bombay Stock Exchange and National Stock Exchange.
In the year 2004, the company invested an amount of Rs 3035.21 lakh towards capital expenditure at their manufacturing facilities at Choutuppal (Unit-I) and Chippada (Unit-II) for additional machinery installed at both Unit-I and Unit-II.
In the year 2006, the company received letter of approval from Ministry of Commerce, Government of India, for setting up a sector-specific special economic zone (SEZ) for pharmaceutical ingredients at Chippada, Bheemunipatnam in Visakhapatnam with investment of Rs 200 crore. The company's second manufacturing site at Chippada, was converted into Export Oriented Unit (EOU) and started operations as EOU from June 1, 2006.
During the year 2006-07, the company developed an SEZ titled 'Divi's Pharma SEZ' on a 250-acre site at Chippada, Visakhapatnam. During the year 2007-08, the company set up new production as well as utility facilities in SEZ and EOU Units, and enhanced existing capacities at Unit-1. They commissioned Nutraceuticals Manufacturing facility at Divi's Pharma SEZ and commenced commercial operations effective June 1, 2008.
During the year 2008-09, the company added 9 products to their product portfolio of which 4 are generic APIs and intermediates and 5 are custom synthesis APIs and intermediates. During the year 2009-10, they added 7 products to their product portfolio of which 2 are generic APIs and intermediates and 5 are custom synthesis APIs and intermediates.
During the year 2010-11, the company added 21 products to their product portfolio of which 8 are generic APIs and intermediates and 13 are custom synthesis APIs and intermediates. The company set up a new facility called 'DSN SEZ Unit' at Chippada in Visakhapatnam at an estimated cost of Rs 200 crore for creating additional capacities for the new opportunities in generic as well as custom synthesis segment. The DSN SEZ Unit commenced commercial operations from June 1, 2011.
During the year 2012-13, the company added 9 products to its product portfolio of which 3 are generic APIs and intermediates and 6 are custom synthesis APIs and intermediates.
In 2014, the Korean Food and Drug Administration (KFDA) carried out inspection of the company's Visakhapatnam Unit-2 for the third time. During the year, fourth US FDA inspection was carried out at the company's Visakhapatnam Unit-2. Also during the year, fifth US FDA inspection was carried out for Unit-1. During the year, COFEPRIS (Mexico) inspected the company's Visakhapatnam Unit-2 for the first time. COFEPRIS (Mexico) also inspected the company's Choutuppal Unit-1 in Telangana for the first time in the year 2014.
On 19 February 2016, Divi's Laboratories announced that it has had a successful inspection by the US-FDA for its Unit-2 at Chippada, Bheemunipatnam near Visakhapatnam during February 2016 with no observations.
The Board of Directors of Divi's Laboratories at its meeting held on 12 August 2016 approved and ratified one-time ex-gratia of an aggregate amount of Rs 79 crore to the employees and whole-time directors of the company on the occasion of completion of 25 years of formation of the company.
On 8 April 2017, Divi's Laboratories announced that the US-FDA has exempted some more products manufactured at the company's Unit-II at Visakhapatnam from import alert issued under clauses 66-40 and 99-32 of the FDA regulations.
On 22 April 2017, Divi's Laboratories announced that the US-FDA has issued a warning letter for the company's Unit-II at Visakhapatnam. On 4 August 2017, Divi's Laboratories announced that the inspection of the Unit-2 Visakhapatnam was completed successfully by HPRA (Ireland) and JAZMP (Slovenia). The inspection was focused on follow up on the effectiveness of the CAPA implemented from the last JAZMP inspection and general GMP inspection of the site.
On 15 November 2017, Divi's Laboratories announced that the US-FDA has lifted/removed import alert 66-40 imposed on the company's Unit-II at Visakhapatnam.
On 18 November 2017, Divi's Laboratories announced that the company has received an Establishment Inspection Report (EIR) from US-FDA for Unit-II at Visakhapatnam, as closure of audit by FDA.
On 16 May 2018, Divi's Laboratories announced that its Unit-I at Choutuppal, Telangana has had an inspection by the US-FDA from 14th May 2018 to 16th May, 2018. This was a general cGMP inspection by the FDA. The inspection has been concluded with no 483 observations.
As on 31 March 2018, the company has two overseas subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products.
During the year 2017-18, the company is making capacity additions at the existing manufacturing facilities and in this process we are building 2 additional production blocks at Unit-1 at Choutuppal. Capital WIP as at the year-end amounted to Rs 11976 lakhs. Capital expenditure incurred at the existing Units is to enhance capacities as well as upgrading utilities and infrastructure for compliances. As the company has significant accumulation of cash reserves, all capex has been funded with internal accruals.
In order to cater to the increasing opportunities in generic and big pharma business, the Company during the FY2019, is taking up following two brownfield projects with an aggregate investment of Rs 1200 crore.a. An SEZ Unit at our Unit-II at Visakhapatnam, named as DCV SEZ Unit, with an investment of Rs 600 crore. (revised from the estimate of Rs 400 crore announced at the last General Meeting),b. Another SEZ Project with an investment of Rs 600 crore in the available land at our Unit-I in Bhuvangiri-Yadadri (erstwhile Nalgonda) District, Telangana State.
The Company has commenced commercial operations from a part of the DC-SEZ Unit in February, 2020, and from a part of the DCV-SEZ Unit in March 2020. The Company has also taken up debottlenecking programs at Unit-I as well as Unit-II by investing an aggregate amount of Rs 300 crore -which would also create additional capacities for existing products. In addition, the company also taken up augmentation of waste treatment infrastructure at Unit-II at an estimated cost of Rs 150 crore. A part of the backward integration, debottlenecking and utility expansion projects have come into utilization this year. The rest of these projects will be completed and come into utilization by end of second half of financial year 2020-21. The balance works of the brownfield projects of DC-SEZ and DCVSEZ are also expected to be completed by second half of financial year 2020-21.
As on 31 March 2020, the company has two overseas subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products.
Eventhough there was a nationwide lockdown restrictions due to COVID-19 pandemic since March 24, 2020, the Government has exempted manufacturing units of essential goods including drugs and pharmaceuticals, medical devices, their raw materials and intermediates from the lockdown restrictions, amongst others. The Company has been operating in compliance with the various advisories/ guidelines passed by the Government of India, State Governments and statutory institutions.
The new brownfield DC and DCV SEZ Units and the debottlenecking / backward integration programs taken up by the company during the last year, have become fully operational during the FY2021. Also Modernization and upgradation of waste water treatment plants at the manufacturing sites has been implemented. During the year 2020-21, the company also taken up another capex program with an estimated investment of Rs 400 crore for fast-tracking a customs synthesis project.
In April, 2023, Company implemented its project of setting up a manufacturing plant (Unit-III) at Kakinada District of Andhra Pradesh.
Divis Laboratories Ltd share price is for NSE ₹ 6,498.00 & for BSE ₹ 6,490.80 as on Nov 27 2025 03:29 PM.
The market cap of Divis Laboratories Ltd for NSE ₹ 1,72,501.50 & for BSE ₹ 1,72,310.30 as on Nov 27 2025 03:29 PM.
The 52 Week High and Low of Divis Laboratories Ltd for NSE is ₹ 7,071.50 and ₹ 4,955.00 and for BSE is ₹ 7,077.70 and ₹ 4,941.70.
The 1 year returns on the stock has been 7.20%.
As on Nov 27 2025 03:29 PM the price-to-earnings (PE) ratio for Divis Laboratories Ltd share is 68.77.
As on Nov 27 2025 03:29 PM, the price-to-book (PB) ratio for Divis Laboratories Ltd share is 578.26.
You can trade in Divis Laboratories Ltd shares with Bajaj Broking by opening a demat account.
To buy Divis Laboratories Ltd shares on the Bajaj Broking app, follow these steps:
• Login to the Bajaj Broking App
• Click on the Search Icon
• Search “Divis Laboratories Ltd”
• Click on the BUY icon
• Place a buy order specifying the desired quantity of shares.
• Click BUY again to complete the purchase
No results found
